Krystal Biotech, Inc. KRYS Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s investment proceeds?
- Krystal Biotech, Inc. (KRYS) reported investment proceeds of $103.6M in Q1 2026.
- How has Krystal Biotech, Inc.'s investment proceeds changed year-over-year?
- Krystal Biotech, Inc.'s investment proceeds increased by 16.7% year-over-year, from $88.81M to $103.6M.
- What is the long-term trend for Krystal Biotech, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s investment proceeds has grown at a 85.1% compound annual growth rate (CAGR), from $32.03M to $375.64M.
- What does investment proceeds mean?
- Cash received from the maturity or sale of financial investments.
- How do you interpret investment proceeds?
- High proceeds indicate the conversion of investment assets back into cash, often to fund operational needs or R&D milestones.
- How does investment proceeds compare across companies?
- Reflects the company's treasury cycle and liquidity management strategy relative to peers.